BY 2018, AVEO PHARMACEUTICALS’ TIVOZANIB WILL GARNER SALES OF UP TO $100 MILLION IN THE RENAL CELL CARCINOMA DRUG MARKET

Tivozanib Is Expected to Launch in 2013 in the United States and Europe, According to Findings from Decision Resources

February 4, 2010 Waltham, Mass. – Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that AVEO Pharmaceuticals’ tivozanib, which is expected to launch in 2013 in the United States and Europe and in 2016 in Japan, will garner sales of up to $100 million by 2018 in the renal cell carcinoma drug market.   

The Pharmacor 2010 findings from the topic entitled Renal Cell Carcinoma show that interviewed thought leaders are optimistic about the potential of the angiogenesis inhibitor tivozanib, which began phase III clinical development in December, 2009. Tivozanib, which is also in early-phase development for breast cancer and non-small-cell lung cancer, will garner six percent of the overall renal cell carcinoma drug market in 2018.

Following its launch, tivozanib will compete with several established and emerging agents in the renal cell carcinoma market, including the current market leader—Pfizer’s Sutent—as well as Bayer Healthcare’s Nexavar, Pfizer’s Torisel, GlaxoSmithKline’s Votrient/Patorma, Novartis’s Afinitor and Pfizer’s axitinib.

“Thought leaders we interviewed are encouraged by tivozanib’s Phase II data and they are optimistic about its potential for treating renal cell carcinoma,” said Decision Resources Analyst Karen Pomeranz, Ph.D. “One expert in the U.S. said tivozanib appears to be a very potent drug with limited side effects.”

The Pharmacor 2010 findings also reveal that the renal cell carcinoma market will increase from $949 million in 2008 to nearly $1.6 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Market growth will be driven by the uptake of emerging therapies—most notably GlaxoSmithKline’s Votrient/Patorma—as well as increases in diagnosis and treatment rates of the disease.

About Pharmacor 2010
The newly redesigned Pharmacor advisory service offers clients in the biopharmaceutical industry the most up-to-date information available on commercially significant disease topics.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

###

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:


Christopher Comfort
Decision Resources Group
781-993-2597
ccomfort@dresources.com
 


Search Reports

Decision Resources Group brands include: